Myriad Genetics Q1 2025: Contradictions Unraveled on GeneSight Performance, Oncology Focus, and EMR Integration
Earnings DecryptTuesday, May 13, 2025 4:41 am ET
2min read
None
Revenue Decline and Strategic Adjustments:
- Myriad Genetics reported a decline in revenue by 3% year-over-year in Q1 2025, representing a significant drop from their targets.
- This decline was attributed to underperformance in GeneSight and myRisk for unaffected individuals, impacted by UnitedHealthcare policy changes and slower-than-expected ramp in system integrations.
Prenatal and Onco Segment Growth:
- The prenatal testing revenue grew by 11% year-over-year, driven by deeper sales into existing accounts and new account wins, particularly with the launch of Prequel at 8 weeks gestational age.
- The oncology segment, particularly myRisk, showed 11% year-over-year growth in test volume, highlighting the strength in their hereditary cancer testing offerings.
GeneSight Challenges and Guidance Adjustments:
- GeneSight revenue declined by 20% year-over-year primarily due to the impact of UnitedHealthcare's coverage policy change, affecting $10 million in revenue.
- The company updated its 2025 financial guidance, reducing annual revenue by $35 million and OpEx by $25 million, reflecting the expected softer volume and reduced commercial resources.
Strategy and Leadership Changes:
- Sam Raha, the new President and CEO, emphasized the need for a strategy that drives profitable growth and market share, focusing on oncology as the cornerstone of Myriad's operations.
- The company is conducting a strategy refresh, aiming to simplify the narrative and prioritize efforts that enable predictable, profitable growth.
![]()
Revenue Decline and Strategic Adjustments:
- Myriad Genetics reported a decline in revenue by 3% year-over-year in Q1 2025, representing a significant drop from their targets.
- This decline was attributed to underperformance in GeneSight and myRisk for unaffected individuals, impacted by UnitedHealthcare policy changes and slower-than-expected ramp in system integrations.
Prenatal and Onco Segment Growth:
- The prenatal testing revenue grew by 11% year-over-year, driven by deeper sales into existing accounts and new account wins, particularly with the launch of Prequel at 8 weeks gestational age.
- The oncology segment, particularly myRisk, showed 11% year-over-year growth in test volume, highlighting the strength in their hereditary cancer testing offerings.
GeneSight Challenges and Guidance Adjustments:
- GeneSight revenue declined by 20% year-over-year primarily due to the impact of UnitedHealthcare's coverage policy change, affecting $10 million in revenue.
- The company updated its 2025 financial guidance, reducing annual revenue by $35 million and OpEx by $25 million, reflecting the expected softer volume and reduced commercial resources.
Strategy and Leadership Changes:
- Sam Raha, the new President and CEO, emphasized the need for a strategy that drives profitable growth and market share, focusing on oncology as the cornerstone of Myriad's operations.
- The company is conducting a strategy refresh, aiming to simplify the narrative and prioritize efforts that enable predictable, profitable growth.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet